Literature DB >> 16957803

Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies.

Donna L McLean1, Scot H Simpson, Finlay A McAlister, Ross T Tsuyuki.   

Abstract

BACKGROUND: Many patients with diabetes also have hypertension, greatly increasing their risk for cardiovascular disease. It has been suggested that hypertension is poorly treated in those with diabetes.
OBJECTIVE: To examine treatment and control of hypertension in people with diabetes. DATA SOURCES: Data sources included MEDLINE, EMBASE, HealthSTAR, CINAHL, Web of Science, clinical evidence and government health and statistical Web sites.
METHOD: Databases were systematically reviewed and hand searches of the bibliographies of relevant studies (1990 to 2004) were conducted. Two investigators selected studies and extracted the data independently.
RESULTS: A total of 44 studies (77,649 subjects with diabetes, 47,964 [62%] of whom also had hypertension) were included. While 83% (range 32% to 100%) of patients with hypertension received drug therapy, only 12% (range 6% to 30%) had their blood pressure (BP) controlled to 130/85 mmHg or less. While BP control rates differed by definition of control (those studies with the least stringent definitions for BP control--160/90 mmHg or less--reported mean control rates of 37%), treatment and control rates did not differ appreciably between countries or health care settings.
CONCLUSIONS: Fewer than one in eight people with diabetes and hypertension have adequately controlled BP, with remarkable uniformity across studies conducted in a variety of settings. There is an urgent need for multidisciplinary, community-based approaches to manage these high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957803      PMCID: PMC2569016          DOI: 10.1016/s0828-282x(06)70304-x

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  62 in total

1.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Authors:  A I Adler; I M Stratton; H A Neil; J S Yudkin; D R Matthews; C A Cull; A D Wright; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

Review 2.  The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future.

Authors:  F A McAlister; N R Campbell; K Zarnke; M Levine; I D Graham
Journal:  CMAJ       Date:  2001-02-20       Impact factor: 8.262

3.  Coronary artery disease, microalbuminuria and lipid profile in patients with non-insulin dependent diabetes mellitus.

Authors:  L Bahia; M B Gomes; M da Cruz P di; M de F Gonçalves
Journal:  Arq Bras Cardiol       Date:  1999-07       Impact factor: 2.000

4.  Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus.

Authors:  S Katayama; M Inaba; T Morita; T Awata; K Shimamoto; R Kikkawa
Journal:  Hypertens Res       Date:  2000-11       Impact factor: 3.872

Review 5.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

6.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

7.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

8.  Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.

Authors:  Lauren C Brown; Jeffrey A Johnson; Sumit R Majumdar; Ross T Tsuyuki; Finlay A McAlister
Journal:  CMAJ       Date:  2004-11-09       Impact factor: 8.262

9.  Treatment of hypertension in a managed care setting.

Authors:  L DiTusa; A B Luzier; D E Jarosz; B D Snyder; J L Izzo
Journal:  Am J Manag Care       Date:  2001-05       Impact factor: 2.229

10.  [Description of type 2 diabetes mellitus in residents of Ile-de-France aged at most 70 years].

Authors:  L Silvera; D Simon; B Trutt; B Blanchon; M Parmentier; P Hecquard
Journal:  Diabetes Metab       Date:  2000-09       Impact factor: 6.041

View more
  17 in total

1.  Hypertension and Health-Related Quality of Life (HRQoL): Evidence from the US Hispanic Population.

Authors:  Elizabeth Riley; Jongwha Chang; Chanhyun Park; Sean Kim; Inho Song
Journal:  Clin Drug Investig       Date:  2019-09       Impact factor: 2.859

2.  Adherence to antihypertensive medications among family practice patients with diabetes mellitus and hypertension.

Authors:  Nandini Natarajan; Wayne Putnam; Kristine Van Aarsen; Kristine Beverley Lawson; Fred Burge
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

3.  Hypertension treatment and control rates: chart review in an academic family medicine clinic.

Authors:  Sara J Houlihan; Scot H Simpson; Andrew J Cave; Nigel W Flook; Mary E Hurlburt; Chris J Lord; Linda L Smith; Harvey H Sternberg
Journal:  Can Fam Physician       Date:  2009-07       Impact factor: 3.275

4.  Drug management for hypertension in type 2 diabetes in family practice.

Authors:  Wayne Putnam; Farokh Buhariwalla; Kendrick Lacey; Mary Goodfellow; Rose Anne Goodine; Jennifer Hall; Ian Macdonald; Michael Murray; Preston Smith; Fred Burge; Nandini Natarajan; Beverley Lawson
Journal:  Can Fam Physician       Date:  2009-07       Impact factor: 3.275

5.  Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP).

Authors:  Charlotte Jones; Scot H Simpson; Diana Mitchell; Susan Haggarty; Norman Campbell; Karen Then; Richard Z Lewanczuk; Rolf J Sebaldt; Barbara Farrell; Lisa Dolovitch; Janusz Kaczorowski; Larry W Chambers
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

6.  Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease.

Authors:  Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Eric J MacLaughlin; James Hoehns; Oralia V Bazaldua; Timothy J Ives; David L Hahn; Christopher S Coffey; Barry L Carter
Journal:  Pharmacotherapy       Date:  2018-02-23       Impact factor: 4.705

7.  Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry.

Authors:  Thomas Mengden; Uwe Ligges; Johanna Mielke; Peter Bramlage; Andrea Korzinek; Walter Sehnert
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-11       Impact factor: 3.738

8.  Determinants of uncontrolled hypertension in adult type 2 diabetes mellitus: an analysis of the Malaysian diabetes registry 2009.

Authors:  Boon How Chew; Ismail Mastura; Sazlina Shariff-Ghazali; Ping Yein Lee; Ai Theng Cheong; Zaiton Ahmad; Sri Wahyu Taher; Jamaiyah Haniff; Feisul Idzwan Mustapha; Mohd Adam Bujang
Journal:  Cardiovasc Diabetol       Date:  2012-05-18       Impact factor: 9.951

9.  Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.

Authors:  Elijah Saunders; Greg Cable; Joel Neutel
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

10.  Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation.

Authors:  Ina-Maria Rückert; Werner Maier; Andreas Mielck; Sabine Schipf; Henry Völzke; Alexander Kluttig; Karin-Halina Greiser; Klaus Berger; Grit Müller; Ute Ellert; Hannelore Neuhauser; Wolfgang Rathmann; Teresa Tamayo; Susanne Moebus; Silke Andrich; Christa Meisinger
Journal:  Cardiovasc Diabetol       Date:  2012-10-05       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.